LUMAKRAS

LUMAKRAS is a prescribed medication for adults diagnosed with non-small cell lung cancer (NSCLC) that has metastasized or is inoperable, and whose tumor contains an abnormal KRAS G12C gene. This medication is suitable for patients who have already undergone at least one prior treatment for their cancer.

For complete Important Safety Information for LUMAKRAS, refer to page 3. Also, refer to the full Prescribing Information for LUMAKRAS. It is important to note that LUMAKRAS has the potential to cause hepatotoxicity, resulting in drug-induced liver injury and hepatitis.

LUMAKRAS is available in the form of film-coated tablets for oral administration. Each tablet contains either 320 mg or 120 mg of sotorasib.

According to a study presented at the 2022 European Society of Medical Oncology Congress, the survival rate with Lumakras was 24.8% at 12 months, compared to 10.1% with the chemotherapy agent docetaxel (Taxotere), at a median of 17.7 months.

Lumakras starts to take effect after the first dose, but it may take several weeks for the drug to have an impact on NSCLC. Due to its mechanism of action, you may not feel the drug working in your body.

You may experience symptoms such as nausea, vomiting, diarrhea, constipation, muscle/joint pain, or tiredness. If any of these symptoms persist or worsen, please inform your doctor or pharmacist immediately.

Sotorasib demonstrated a 41% objective response rate (ORR), with a median duration of response (DoR) of 12.3 months. The progression-free survival (PFS) was 6.3 months, while the overall survival (OS) was 12.5 months, with a 2-year OS rate of 33%. Notably, 23% of patients experienced long-term clinical benefit, defined as a PFS of 12 months or longer, regardless of their PD-L1 expression levels. This benefit was observed in a subset of patients with somatic STK11 and/or KEAP1 alterations.

Sotorasib demonstrated an objective response rate (ORR) of 41%, with a median duration of response of 12.3 months. The progression-free survival (PFS) was 6.3 months, while the overall survival (OS) was 12.5 months. Additionally, the 2-year OS rate was reported to be 33%.

Lumakras (sotorasib) is a medication that belongs to the RAS GTPase inhibitor family. It is prescribed to adults who have been diagnosed with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as confirmed by an FDA-approved test, and have previously undergone at least one systemic therapy.

Lumakras has received orphan drug designation from the FDA for the treatment of KRAS G12C-positive non-small cell lung cancer (NSCLC) and colorectal cancer.

It is crucial to recognize that sotorasib operates differently from traditional chemotherapy drugs. Instead of attacking all rapidly dividing cells, it specifically targets cancer cells to inhibit their growth and spread.

As of May 2021, LUMAKRAS became the inaugural KRASG12C inhibitor to be granted regulatory approval in the United States, utilizing an accelerated approval process. Since then, more than 15,000 patients globally have been treated with LUMAKRAS/LUMYKRAS through various channels including the clinical development program, early access programs, and commercial use.

Lumakras is a medication used as a second-line treatment for non-small cell lung cancer (NSCLC). It is prescribed to patients who have already undergone at least one previous systemic treatment for their cancer. Unlike chemotherapy or immunotherapy, Lumakras works as an inhibitor specifically targeting the KRAS G12C mutation.

To take LUMAKRAS®, you should consume eight 120 mg tablets orally once daily, with or without food.

Demonstrating the clinical effectiveness of sotorasib as a standalone treatment for advanced NSCLC patients with the KRASG12C mutation who have undergone prior anticancer therapy, with an overall response rate of 37.1%, a median progression-free survival of 6.8 months, and a median overall survival of 12.5 months.

If you need LUMAKRAS®, your healthcare provider can assist you in locating a specialty pharmacy that accepts your insurance. Once your insurance coverage is confirmed, the specialty pharmacy will reach out to you to arrange for the delivery of your prescription.

The price of a 240-tablet supply of Lumakras oral tablets 120 mg can vary depending on the pharmacy, but it is typically around $21,186.

Lumakras is typically listed on Tier 5 of Medicare prescription drug plans’ formulary, which means that the cost of the medication is generally higher.

If you and your doctor agree that Lumakras is safe and effective for you, it is intended for long-term use.

Symptoms may include nausea, diarrhea, cough, liver problems, muscle, joint, or bone pain, tiredness, or abnormal blood tests.

Sotorasib demonstrated an objective response rate (ORR) of 41%, with a median duration of response of 12.3 months. The progression-free survival (PFS) was 6.3 months, while the overall survival (OS) was 12.5 months. Additionally, the 2-year OS rate was reported to be 33%.

The cost of Lumakras, a lung-cancer treatment released in 2021, was $17,900 per patient per month.

This drug is covered by all Medicare prescription drug plans, with a coverage rate of 100%.

LUMAKRAS is utilized in the treatment of non-small cell lung cancer (NSCLC), specifically targeting the abnormal protein KRAS G12C. By binding to this protein, LUMAKRAS inhibits its function in tumor cells.

Generic Name: sotorasib
Indication: This medication is prescribed for the treatment of non-small cell lung cancer (NSCLC). It functions by inhibiting the growth of cancer cells, thereby slowing down or halting their progression.

Lumakras is a specialty medication that can only be obtained at specialty pharmacies, not at retail pharmacies such as CVS or Walgreens.

Your healthcare provider can assist you in locating a specialty pharmacy that collaborates with your insurance. Upon verifying your insurance coverage, the specialty pharmacy will reach out to you to arrange the delivery of your prescription.

Lumakras, also known as sotorasib, is a medication that belongs to the RAS GTPase inhibitor family. It is prescribed to adults who have KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). This prescription is determined by an FDA-approved test and is given to patients who have already undergone at least one prior systemic therapy.